Servier has nine glioma abstracts for SNO 2026, but can the data expand its treatment reach?
Servier reveals its SNO 2026 plans for Voranigo and Ojemda, with long-term glioma outcomes, treatment durability and potential expansion in focus.
Pharma & Biotech
Pharma & Biotech
Why Servier’s FIREFLY-2 enrollment milestone could reshape pediatric glioma treatment
OJEMDA is already approved after relapse. FIREFLY-2 asks whether Servier can move targeted pLGG therapy earlier.
Pharma & Biotech
Why Servier’s $2.5bn acquisition of Day One Biopharmaceuticals could reshape the pediatric glioma treatment landscape
Servier plans a $2.5B acquisition of Day One Biopharmaceuticals to expand its rare oncology pipeline. Discover what the deal means for pediatric glioma.
Pharma & Biotech
Ipsen moves closer to EU approval for Ojemda in BRAF-driven childhood brain tumors
Ipsen nears EU approval for Ojemda in BRAF-driven pediatric glioma. Explore regulatory impact, clinical implications, and long-term risks.